|
Papillary thyroid carcinoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
In our study, BRAF V600E mutation revealed a strong association with specific histological variants of PTC: highly specific for CPTC, tall cell or oncocytic PTC, but negative in all cases of FVPTC.
|
22732794 |
2012 |
|
Papillary thyroid carcinoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
It has been suggested that patients with papillary thyroid cancer (PTC) harbouring the BRAF(V600E) mutation have a worse prognosis.
|
22702340 |
2012 |
|
Papillary thyroid carcinoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
These resu</span>lts suggest that BRAF(V599E) mutation is frequent in the etiopathogenesis of PTC.
|
12881714 |
2003 |
|
Papillary thyroid carcinoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
BRAF V600E detection in cytological thyroid samples: A key component of the decision tree for surgical treatment of papillary thyroid carcinoma.
|
26854757 |
2016 |
|
Papillary thyroid carcinoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
In summary, BRAF V600E-activated MAP kinase pathway causes hypomethylation and overexpression of WIPF1; WIPF1 then functions like an oncoprotein to robustly promote aggressive cellular and tumor behaviors of PTC.
|
27863429 |
2017 |
|
Papillary thyroid carcinoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
Vemurafenib showed antitumour activity in patients with progressive, BRAF(V600E)-positive papillary thyroid cancer refractory to radioactive iodine who had never been treated with a multikinase inhibitor.
|
27460442 |
2016 |
|
Papillary thyroid carcinoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
In this study, we used an automated immunohistochemistry (IHC) staining coupled with mouse monoclonal anti-BRAF V600E (VE1) primary antibody to screen the BRAF V600E mutation in 779 tumor cases, including 611 colorectal carcinomas (CRC), 127 papillary thyroid carcinomas (PTC) and 41 malignant melanomas.
|
25784606 |
2015 |
|
Papillary thyroid carcinoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
<i>BRAF</i>V600E (c.1799T>A) somatic mutation evaluation in fine needle aspiration biopsies (FNAB) is a powerful diagnostic tool in the settings of papillary thyroid cancer (PTC).
|
30374428 |
2018 |
|
Papillary thyroid carcinoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
In this article we will review the relation between B-Raf(V600E) and PTC, as well as both non-selective and selective pharmacological agents currently under investigation for treatment of B-Raf(V600E) positive PTC.
|
19356676 |
2009 |
|
Papillary thyroid carcinoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
In papillary thyroid cancer (PTC) and papillary-derived anaplastic thyroid cancer (ATC), the BRAF(V600E) mutation promotes follicular cell transformation.
|
25961545 |
2015 |
|
Papillary thyroid carcinoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
The immunocytochemical expression of VE-1 (BRAF V600E-related) antibody identifies the aggressive variants of papillary thyroid carcinoma on liquid-based cytology.
|
30875124 |
2019 |
|
Papillary thyroid carcinoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
Approximately 45% of papillary thyroid carcinomas harbor BRAF p.V600E mutations and current practice algorithms endorse molecular testing for BRAF p.V600E.
|
24897065 |
2014 |
|
Papillary thyroid carcinoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
Thus, this study, the largest on TERT mutation so far, demonstrates a significant role of BRAF V600E and TERT promoter mutations in the aggressiveness of PTC, which is particularly robust and cooperative when the two mutations coexist.
|
26943032 |
2016 |
|
Papillary thyroid carcinoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
These data indicate that BRAF(V600E) is associated some of the aggressive clinicopathological features of PTC including younger age at diagnosis, larger tumor size, and classic histological type, as well as also extrathyroidal invasion.
|
19355825 |
2009 |
|
Papillary thyroid carcinoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
Dabrafenib can stimulate radioiodine uptake in patients with metastatic BRAF V600E-mutant iodine-refractory PTC, representing a potential new therapeutic approach for these patients.
|
25549723 |
2015 |
|
Papillary thyroid carcinoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
BRAF V600E mutations may be more prevalent than previously thought in pediatric patients with PTC, but do not correlate with aggressive disease characteristics.
|
24604709 |
2014 |
|
Papillary thyroid carcinoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
BRAF(V600E) mutation detected on FNAB specimens, more than RET/PTC rearrangements, is highly specific for PTC and its routine research might well be an adjunctive and integrative diagnostic tool for the preoperative diagnostic iter.
|
17727338 |
2007 |
|
Papillary thyroid carcinoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
IHC is a suitable method to screen BRAF V600E mutation in FFPE samples of CRCs and PTCs.
|
30009773 |
2018 |
|
Papillary thyroid carcinoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
The Association of BRAF V600E Mutation With Tissue Inhibitor of Metalloproteinase-3 Expression and Clinicopathological Features in Papillary Thyroid Cancer.
|
29868127 |
2018 |
|
Papillary thyroid carcinoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
BRAF(V600E) mutation analysis from May-Grünwald Giemsa-stained cytological samples as an adjunct in identification of high-risk papillary thyroid carcinoma.
|
21948220 |
2011 |
|
Papillary thyroid carcinoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
RET/PTC rearrangement and BRAF(V600E) mutation are the two prevalent molecular alterations associated with papillary thyroid carcinoma (PTC), and their identification is increasingly being used as an adjunct to cytology in diagnosing PTC.
|
23722226 |
2013 |
|
Papillary thyroid carcinoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
BRAF V600E was found in 70% of the papillary thyroid cancers; there were no RAS mutations.
|
25019383 |
2014 |
|
Papillary thyroid carcinoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
Further, type I collagen enhanced the motility of Braf(V600E)/Pten(-/-)/TPO-Cre tumor cells in vitro In clinical specimens, we found COL1A1 and LOX to be upregulated in PTC and expressed at highest levels in PDTC and anaplastic thyroid cancer.
|
26818109 |
2016 |
|
Papillary thyroid carcinoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
Diagnostically, the BRAF(V600E) mutation is a powerful molecular marker for papillary thyroid carcinoma and, quite possibly, hairy cell leukemia as well.
|
22369373 |
2012 |
|
Papillary thyroid carcinoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
CD70 expression was associated with the presence of a precursor papillary thyroid carcinoma and the presence of BRAF V600E mutations in the anaplastic thyroid cancer lesion.
|
28383817 |
2017 |